Brief: 5-Year Phase 2 Data Show Transcon® Pth Replicated Systemic Actions Of Endogenous Pth In Adults With Hypoparathyroidism

Ascendis Pharma A/S

11/06/2026 21:34

June 11 (Reuters) - Ascendis Pharma A/S A71.F:
5-YEAR PHASE 2 DATA SHOW TRANSCON® PTH REPLICATED SYSTEMIC ACTIONS OF ENDOGENOUS PTH IN ADULTS WITH HYPOPARATHYROIDISM
ASCENDIS PHARMA A/S - TRANSCON PTH TREATMENT GENERALLY WELL-TOLERATED WITH NO NEW SAFETY SIGNALS
ASCENDIS PHARMA A/S - 5-YEAR PHASE 2 DATA SHOW 82% RESPONSE RATE FOR MULTI-COMPONENT ENDPOINT AT WEEK 266
ASCENDIS PHARMA A/S - PATIENTS REPORTED IMPROVED SYMPTOMS AND QUALITY OF LIFE THROUGH WEEK 266
ASCENDIS PHARMA A/S - 5-YEAR PHASE 2 DATA SHOWS 95% OF PATIENTS COMPLETED FIVE YEARS OF TREATMENT
Source text: ID:nGNXc4j9vv
Further company coverage: A71.F

 ((Reuters.Briefs@thomsonreuters.com;))